

20 **Author Involvement:** All authors had access to the data, a role in writing, reviewing, and
21 approving the manuscript.

22

23

24 **Abstract**

25 **Importance:** The development and importance of ambulatory hypoxia in COVID-19 is
26 unknown. The presence of ambulatory hypoxia may help risk-stratify hospitalized patients with
27 COVID-19. If sufficient lead-time exists between development of ambulatory hypoxia and other
28 outcome measures, interventions might be initiated earlier.

29 **Objective:** To determine the association of ambulatory hypoxia with the eventual need for nasal
30 cannula or advanced oxygenation therapies (defined as use of high flow nasal cannula, Bi-PAP,
31 ventilator, or extracorporeal membrane oxygenation).

32 **Design:** Retrospective, observational study of patients hospitalized with COVID-19 from March
33 1, 2020 to October 30, 2020.

34 **Setting:** Ten hospitals in an integrated academic medical system (Northwestern Medicine) in the
35 Chicagoland area.

36 **Participants:** Adult patients (age \geq 18) hospitalized for COVID-19 who had ambulatory
37 oximetry measured.

38 **Intervention(s) / Exposure(s):** Ambulatory oximetry measurement.

39 **Main outcomes and measures:** The association of ambulatory hypoxia with subsequent use of
40 nasal cannula and advanced oxygen therapies and the time between ambulatory hypoxia and
41 need for these oxygen therapies. Patients who had ambulatory oximetry measurements after use
42 of nasal cannula or advanced oxygen therapies were excluded.

43 **Results:** Of 531 patients with ambulatory oximetry measured, 132 (24.9%) had ambulatory
44 hypoxia. Presence of ambulatory hypoxia was strongly associated with subsequent use of nasal

45 cannula (OR 4.8, 95% CI 2.8 – 8.4) and advanced oxygen therapy (IRR 7.7, 95% CI 3.4 – 17.5).

46 Ambulatory hypoxia measurement preceded nasal cannula use by a median 12.5 hours [IQR

47 3.25, 29.25] and advanced oxygenation therapies by 54 hours [IQR 25, 82].

48 **Conclusion and Relevance:** Ambulatory hypoxia is associated with moderate to severe COVID-

49 19. It may serve as an early, non-invasive physiologic marker for the likelihood of developing

50 moderate to severe disease and help clinicians triage patients and initiate earlier interventions.

51 **Introduction**

52 Coronavirus-induced-disease-2019 (COVID-19) has caused a pandemic with 56,178,674
53 cases and 1,348,348 deaths worldwide.¹ In our experience, we noted many inpatients with
54 COVID-19 first exhibit hypoxia with exertion, then subsequently develop moderate to severe
55 disease requiring nasal cannula or more advanced oxygen therapies. Early COVID-19 induces
56 occult lung damage, noted by peripheral ground-glass opacities on imaging.² We suspect patients
57 at this stage exhibit ambulatory but not resting hypoxia. Several studies have characterized risk
58 factors for severe COVID-19 based on patient-specific comorbidities and laboratory data. To our
59 knowledge, no study has evaluated ambulatory hypoxia as a risk factor for development of
60 moderate to severe disease. Therefore, we aimed to evaluate if ambulatory hypoxia is associated
61 with COVID-19 progression.

62 **Methods**

63 We performed a retrospective observational study of adults (age ≥ 18 years) hospitalized
64 with COVID-19 who had ambulatory oxygen measurements (without first developing resting
65 hypoxia) at Northwestern Medicine (NM) between March 1, 2020 and October 30, 2020. NM is
66 an integrated academic medical system in the Chicagoland area with 10 affiliated hospitals. We
67 compared the associations between patients with and without ambulatory hypoxia and the use of
68 nasal cannula (NC) or advanced oxygenation therapy [defined as high flow nasal cannula
69 (HFNC), bi-level positive airway pressure (BiPAP), mechanical ventilation (vent) or
70 extracorporeal membrane oxygenation (ECMO)]. We evaluated the time from the measurement
71 of ambulatory hypoxia to initiation of NC and advanced oxygenation therapies. This study was
72 approved by the Northwestern University Institutional Review Board.

73 *Procedure*

74 We queried the Northwestern University Enterprise Data Warehouse (EDW) for all adult
75 patients hospitalized with COVID-19 (ICD-10 code) who had ambulatory oxygen levels
76 measured. The EDW is a complete database of clinical data extracted from the electronic
77 medical records at NM. Hospital protocols within NM recommend that all patients with COVID-
78 19 have once daily ambulatory oximetry screening, if able to participate. Any ambulatory
79 oxygen saturation below 90% was considered hypoxia. Oxygen therapy outcomes included need
80 for NC, HFNC, BiPAP, vent, and ECMO. Date and time of ambulatory hypoxia and initiation of
81 all oxygen therapy outcomes were recorded. We *excluded* patients in whom oxygen therapy
82 outcomes occurred before ambulatory pulse oximetry measurement as well as those who were
83 still hospitalized at the end of the study period.

84 Patient demographic and clinical data on admission including age, sex, race and ethnicity,
85 body mass index (BMI), D-dimer, ferritin, and c-reactive protein (CRP) were recorded. The
86 EDW query also included all ICD-10 codes for pre-existing chronic conditions. The Charlson
87 comorbidity index for each patient was calculated based on admission ICD-10 codes to account
88 for severity of illness at admission. For patients with multiple admissions, only data and
89 outcomes during a chronologically first ‘index’ encounter were evaluated. Age, BMI, Charlson,
90 D-dimer, CRP, and ferritin values were categorized for ease of interpretation. Time between
91 ambulatory hypoxia and use of NC or advanced oxygen therapies was measured using the first
92 occurrence of the oxygen therapy outcome.

93 *Analysis*

94 Chi-square tests were used to evaluate bivariate associations between demographic and
95 clinical variables and the proportion of patients with ambulatory hypoxia and subsequent use of
96 nasal cannula or advanced oxygenation therapy. We used multiple logistic regression of the
97 likelihood of nasal cannula to test the significance of ambulatory hypoxia because NC occurred
98 in 13% of patients. We used multiple Poisson regression of the likelihood of advanced oxygen
99 therapy to test the significance of ambulatory hypoxia because advanced oxygenation occurred in
100 6% of patients.^{3,4} We controlled for patients' demographic and clinical characteristics including
101 age, sex, race and ethnicity, BMI, and Charlson score, plus laboratory values that were
102 significant at $p < 0.1$ in bivariate associations. We performed sensitivity analyses substituting
103 specific ICD-10 diagnoses including atrial fibrillation, coronary artery disease, congestive heart
104 failure, diabetes mellitus, connective tissue disease, chronic obstructive pulmonary disease,
105 hepatic failure with encephalopathy, human immunodeficiency virus, hypertension, leukemia or
106 lymphoma, other immunodeficiencies, peripheral arterial disease, renal disease, solid tumor, and
107 transplant in place of the Charlson score. R (3.6.1, Vienna, Austria) was used for analysis.

108 **Results**

109 Our study included 531 patients with ambulatory oximetry measurements. Of these, 132
110 patients (24.9%) had ambulatory hypoxia. NC was required by 28.8% of patients with
111 ambulatory hypoxia, compared to 8.0% of patients without it ($p = 2.4 \times 10^{-9}$). Advanced
112 oxygenation therapy was required by 18.9% of patients with ambulatory hypoxia, compared to
113 2.3% without it ($p = 4.6 \times 10^{-11}$). Demographic and clinical variables are listed in Table 1.

114 Multiple logistic and Poisson regression results confirmed that the presence of
115 ambulatory hypoxia was strongly associated with the likelihood of using NC (OR 4.8, 95% CI
116 2.8 – 8.4) and advanced oxygenation (IRR 7.7, 95% CI 3.4 – 17.5); Table 2. Results were

117 unchanged in the sensitivity analysis. Ambulatory hypoxia preceded NC use by a median 12.5
118 hours [IQR 3.25, 29.25] and advanced oxygenation therapies by 54 hours [IQR 25, 82].

119 **Discussion**

120 Our study shows that the presence of ambulatory hypoxia is strongly associated with the
121 subsequent development of moderate to severe COVID-19. In our patient population,
122 ambulatory hypoxia occurred several hours before the need for NC and advanced oxygen
123 therapies. This is important because it may enable clinicians to start therapeutic treatments such
124 as remdesivir⁵ and/or dexamethasone⁶ earlier. It may also help health systems effectively identify
125 patients most likely to require ICU-level care, which may improve hospital throughput especially
126 when hospitals are near or at capacity.

127 Ambulatory oximetry has been used to help determine severity of cardiopulmonary
128 diseases including heart failure,⁷ pulmonary hypertension,⁸ chronic obstructive pulmonary
129 disease,⁹ and interstitial lung disease.¹⁰ To our knowledge, the presence of ambulatory hypoxia
130 has never been shown to acutely predict cardiopulmonary disease progression. Recently, some
131 authors have advocated for ambulatory oximetry measurements to evaluate patients for discharge
132 readiness after resolution of COVID-19 symptoms,¹¹ a strategy already adopted in our hospital.
133 We present the first study showing that ambulatory hypoxia predicts worsening pulmonary
134 disease in patients with COVID-19.

135 Our study has several limitations. First our study was performed at one health network
136 with a relatively small number of patients potentially limiting generalizability. However, the
137 associations between ambulatory hypoxia and worsening oxygenation were statistically very
138 strong. Second, we excluded patients who did not have ambulatory oximetry measurements.

139 Ambulatory oxygen measurement is part of the admission order protocols in our health system,
140 so patients without measurements likely represented a sicker cohort unable to ambulate or those
141 discharged quickly. Patients without measurement may also have been cared for by clinicians
142 who did not order ambulatory oximetry, given lacking evidence. Third, we did not directly
143 measure the presence of resting hypoxia because it was often not documented in the medical
144 record before the use of oxygen therapy. The use of oxygen therapy was used as a surrogate for
145 resting hypoxia. Finally, we excluded all patients who used oxygen therapy before ambulatory
146 oximetry measures. These patients likely underwent ambulatory oximetry to determine discharge
147 readiness. Alternatively, there may have been a small number of these patients who were given
148 NC treatment for subjective comfort without resting hypoxia, who then developed ambulatory
149 hypoxia.

150 Future randomized studies should be performed to evaluate earlier interventions in
151 patients with COVID-19 and ambulatory hypoxia without resting hypoxia. An important
152 extension of our findings could be the use of ambulatory oximetry measurement in triaging both
153 outpatients and inpatients with COVID-19. Ambulatory hypoxia may help determine whether
154 admission and inpatient monitoring with continuous pulse oximetry is warranted.

155

156

157

158 **References**

- 159 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet*
160 *Infect Dis* 2020;20(5):533-34. doi: 10.1016/S1473-3099(20)30120-1 [published Online First:
161 2020/02/23]
- 162 2. Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19
163 Pneumonia: A Longitudinal Study. *Radiology* 2020;296(2):E55-E64. doi:
164 10.1148/radiol.2020200843 [published Online First: 2020/03/20]
- 165 3. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of
166 common outcomes. *JAMA* 1998;280(19):1690-1. doi: 10.1001/jama.280.19.1690 [published
167 Online First: 1998/12/01]
- 168 4. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J*
169 *Epidemiol* 2004;159(7):702-6. doi: 10.1093/aje/kwh090 [published Online First: 2004/03/23]
- 170 5. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. *N*
171 *Engl J Med* 2020;383(19):1813-26. doi: 10.1056/NEJMoa2007764 [published Online First:
172 2020/05/24]
- 173 6. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary
174 Report. *N Engl J Med* 2020 doi: 10.1056/NEJMoa2021436 [published Online First: 2020/07/18]
- 175 7. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure:
176 a scientific statement from the acute heart failure committee of the heart failure association of
177 the European Society of Cardiology and endorsed by the European Society of Intensive Care
178 Medicine. *Eur J Heart Fail* 2010;12(5):423-33. doi: 10.1093/eurjhf/hfq045 [published Online
179 First: 2010/04/01]
- 180 8. Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: how far is enough? *Am J Respir*
181 *Crit Care Med* 2012;186(5):396-7. doi: 10.1164/rccm.201206-1137ED [published Online First:
182 2012/09/04]
- 183 9. Stoller JK, Panos RJ, Krachman S, et al. Oxygen therapy for patients with COPD: current evidence and
184 the long-term oxygen treatment trial. *Chest* 2010;138(1):179-87. doi: 10.1378/chest.09-2555
185 [published Online First: 2010/07/08]
- 186 10. Khor YH, Goh NS, Glaspole I, et al. Exertional Desaturation and Prescription of Ambulatory Oxygen
187 Therapy in Interstitial Lung Disease. *Respir Care* 2019;64(3):299-306. doi:
188 10.4187/respcare.06334 [published Online First: 2018/11/01]
- 189 11. Hussain T, Saman HT, Yousaf Z. Identification of Exertional Hypoxia and Its Implications in SARS-CoV-
190 2 Pneumonia. *Am J Trop Med Hyg* 2020;103(4):1742-43. doi: 10.4269/ajtmh.20-1012 [published
191 Online First: 2020/08/28]

192

193

194 **Table 1:** Percentage of Inpatients with COVID-19 with Each Demographics and Clinical
 195 Variable Who Underwent Ambulatory Oximetry and Developed Need For Oxygen Therapies.

Characteristics	All Patients (n=531) %*	Nasal Cannula (n=70) %*	Advanced Oxygenation Therapy (n=34) %*
Ambulatory Hypoxia Present ^a	24.9	7.2	4.7
Age (years) ^b			
< 50	32.0	2.4	1.3
50-59	18.6	2.8	1.1
60-69	23.0	3.8	2.4
≥ 70	26.4	4.1	1.5
Gender			
Male	50.1	6.2	4.0
Female	49.9	7.0	2.4
Race and Ethnicity			
Non-Hispanic White	33.9	5.8	2.1
Hispanic or Latino	34.7	4.0	1.5
Black or African American	21.7	2.1	1.9
Other Races and ethnicities	9.8	1.3	0.9
BMI (kg/m ²) ^c			
< 24.9	21.8	3.0	1.5
25.0 - 29.9	29.2	3.4	1.3
30.0 - 39.9	30.5	3.8	1.7
≥ 40	10.0	2.1	1.5
Unmeasured	8.5	0.9	0.4
Admission D-Dimer (ng/mL)			
0-999	53.1	7.0	3.6
≥ 1000	5.8	0.8	0.8
Unmeasured	41.1	5.5	2.1
Admission Ferritin ^d (ng/mL)			
0 – 499	44.8	4.9	2.4
500 – 999	13.2	1.9	0.8
≥ 1000	11.1	2.1	1.7
Unmeasured	30.9	4.3	1.5
Admission CRP ^c (mg/L)			
0 – 99	55.6	6.8	3.2
100 – 199	13.4	2.6	1.3
≥ 200	4.5	0.9	0.8

Unmeasured	26.6	2.8	1.1
Charlson Score ^e			
0-2	43.5	3.4	2.1
3-5	31.6	4.7	2.3
≥ 6	24.9	5.1	2.1
Atrial Fibrillation	10.0	1.9	0.8
Coronary Artery Disease ^b	4.1	1.1	0.4
Congestive Heart Failure	12.2	2.4	1.1
Diabetes Mellitus	32.4	5.5	2.6
Connective Tissue Disorders	2.8	0.4	0.2
COPD	8.9	1.5	0.8
Liver Failure ^{c,e}	1.1	0.6	0.4
HIV	0.8	0.0	0.0
Hypertension	58.8	8.3	4.3
Leukemia or Lymphoma	9.0	1.7	0.9
Other Immunodeficiencies	0.8	0.4	0.0
Peripheral Artery Disease	3.6	0.8	0.0
Renal Disease ^b	19.0	3.6	1.5
Solid Tumor	4.0	0.4	0.4
Transplant ^b	5.1	1.3	0.6
^a p < 0.0001 for nasal cannula and advanced oxygenation therapy ^b p < 0.1 for nasal cannula ^c p < 0.1 for advanced oxygenation therapy ^d p < 0.05 for advanced oxygenation therapy ^e p < 0.05 for nasal cannula *All percent values are row percents relative to all patients (n=531)			

Table 2: Multiple Logistic and Poisson Regression Results for the Association of Ambulatory Hypoxia with the likelihood of Nasal Cannula or Advanced Oxygenation use in 531 Inpatients with COVID-19.

Characteristics	Nasal Cannula		Advanced Oxygenation	
	OR (95% CI)	p	IRR (95% CI)	p
Ambulatory Hypoxemia Present	4.8 (2.8 - 8.4)	3×10^{-8}	7.7 (3.4 - 17.5)	8×10^{-7}
Age (years)				
< 50*	-	-	-	-
50-59	1.5 (0.6 - 3.6)	0.40	1.0 (0.3 - 3.2)	0.97
60-69	1.2 (0.4 - 3.1)	0.75	1.7 (0.5 - 6.2)	0.40
≥ 70	0.6 (0.2 - 1.8)	0.35	0.9 (0.2 - 4.1)	0.88
Gender				
Male	0.8 (0.5 - 1.4)	0.47	1.6 (0.7 - 3.6)	0.23
Female*	-	-	-	-
Race and Ethnicity				
Non-Hispanic White*	-	-	-	-
Hispanic or Latino	0.8 (0.4 - 1.7)	0.62	0.9 (0.3 - 2.5)	0.85
Black or African American	0.4 (0.2 - 0.9)	0.02	1.3 (0.5 - 3.4)	0.59
Other Races and ethnicities	1.0 (0.4 - 2.6)	0.98	2.1 (0.6 - 6.7)	0.23
BMI (kg/m ²)				
< 25.0*	-	-	-	-
25.0 - 29.9	1.0 (0.5 - 2.2)	0.95	0.7 (0.2 - 1.9)	0.48
30.0 - 39.9	1.0 (0.5 - 2.3)	0.91	0.8 (0.3 - 2.2)	0.64
≥ 40	2.3 (0.9 - 6.2)	0.10	2.6 (0.8 - 7.9)	0.10
Unmeasured	1.1 (0.3 - 3.4)	0.87	0.7 (0.1 - 3.5)	0.65
Admission CRP (mg/L)				
< 100*	-	-	-	-
100 – 199	-	-	1.9 (0.8 - 4.5)	0.96
≥ 200	-	-	1.7 (0.7 - 4.1)	0.81
Unmeasured	-	-	1.1 (0.4 - 2.9)	0.68
Admission Ferritin(ng/mL)				
< 500*	-	-	-	-
500 – 999	-	-	1.5 (0.5 - 4.7)	0.94
≥ 1000	-	-	0.9 (0.3 - 2.6)	0.28
Unmeasured	-	-	1.1 (0.3 - 3.5)	0.77
Charlson Score				
< 3*	-	-	-	-

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

3-5	2.4 (1.1 - 5.5)	0.03	1.4 (0.5 - 3.9)	0.55
≥ 6	4.6 (1.8 - 12.3)	0.002	1.4 (0.4 - 5.1)	0.63
*Denotes reference category				